Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NumeralJSE:XII 18 Interest Coverage is 1.39 as of May. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates JSE:XII with a GF Score™ of 18/100. The stock has 7 warning signs investors should review. Among 682 Drug Manufacturers companies, Numeral ranks worse than 146627.42% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Numeral's
Operating Income
for the
three
months ended in May. 2026 was R2.01 Mil. Numeral's Interest Expense for the
three
months ended in May. 2026 was R-1.45 Mil.
Numeral's interest coverage for the quarter that ended in May. 2026 was 1.39.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Numeral's Interest Coverage or its related term are showing as below:
JSE:XII's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.82 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Numeral Interest Coverage Related Terms
Numeral Interest Coverage Historical Data
* Premium members only.
The historical data trend for Numeral's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
JSE:XII vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Numeral's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Numeral Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Numeral's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Numeral's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Numeral (JSE:XII) has a Interest Coverage of 1.39 as of May. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Numeral and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, Numeral's Interest Coverage has ranged from 1.07 to 10,000.00. According to the industry distribution chart, Numeral ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is Numeral's Interest Coverage too high?
Numeral's current Interest Coverage of 1.39 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 10,000.00. The Drug Manufacturers industry median Interest Coverage is 12.82. Numeral's value of 1.39 is 89.2% below this industry median. Based on the distribution chart, Numeral ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Numeral has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Numeral's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Numeral ranks #999999 out of 682 companies for Interest Coverage. This places Numeral in the lower half of its industry. The industry median Interest Coverage is 12.82. Numeral's value of 1.39 is 89.2% below this benchmark. Historically, Numeral's own Interest Coverage has ranged from 1.07 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 12.82, Numeral has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.82, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Numeral's current Interest Coverage of 1.39 is 89.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Numeral and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Numeral's current Interest Coverage is 1.39, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Numeral stock overvalued right now?
Numeral (JSE:XII) has a current Interest Coverage of 1.39. The current Interest Coverage is 1.39, which is 100% below median its 10-year median of 10,000.00 and 89.2% below the Drug Manufacturers industry median of 12.82. Numeral's overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Numeral (JSE:XII), the current Interest Coverage is 1.39 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Numeral Ltd is an investment holding company based in Mauritius with a focus on fintech, biotechnology, and asset management. Geographically it has a presence in countries across Africa, Europe and Asia. The majority of its revenue is generated in the form of Trading income.
18GF Score
Get the complete analysis for JSE:XII
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:XII has been successfully added to your 
